ClinicalTrials.gg
Not yet recruitingNCT06944600SOMNUS-DAREUpdated Apr 25, 2025

Impact of Sleep Disorders and Digital Support on Older People's Health

An observational study in Sleep Disorders, Frailty and Cognitive Impairment, sponsored by University of Parma. Not yet recruiting. Open to participants aged 65 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-25.

Sponsored by University of Parma · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
65 Years and older
Sex
All
01

Study summary

The goal of this observational study is to learn about the effects of sleep disorders on health and ageing in older people over the age of 65.

The main question it aims to answer is: How do sleep disorders impact the motoric and cognitive ageing trajectories of older individuals? Participants will undergo a set of instrumental, laboratory and clinical diagnostic examinations to comprehensively assess the impact of sleep disorders on health.

02

Conditions studied

  • Sleep Disorders
  • Frailty
  • Cognitive Impairment
  • Quality of Life
  • Ageing
  • Digital Health
  • Multidisciplinary Approach
03

In context

Sleep Wake Disorders

747 studies on the registry are indexed under Sleep Wake Disorders; 181 are open to participants now.

This study's planned enrollment of 300 is above the median of 120 across 197 observational studies indexed under Sleep Wake Disorders.

Browse Sleep Wake Disorders studies →

Lead sponsor

University of Parma is the lead sponsor of 77 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Physically frail sarcopenic and healthy active subjects, from 65 years of age, admitted to the geriatric and sleep medicine outpatient clinic, not demented and independent in the Basic Activities of Daily Living.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years;
  • score adjusted by age and education ≥ 25/30;
  • Absence of mobility-disability;
  • Absence of need for assistance with Basic Activities of Daily Living (according to the ICFSR International Clinical Practice Guidelines).

Exclusion criteria

Exclusion Criteria:

  • Individuals with specific clinical conditions that make the intervention unsafe (I.e., severe diseases, unstable health status);
  • Individuals whose adherence to the protocol might be low due to clinical (E.g., cognitive impairment, dialysis) and non-clinical (E.g., plans to relocate out of the study area within the next 3 years) reasons;
  • Individuals unable or unwilling to provide ;
  • Consumption of more than 14 alcoholic drinks per week [one alcoholic drink (equal to 14.0 grams of pure alcohol) corresponds to 36 cc of beer (5% alcohol content), 24 cc of malt liquor (7% alcohol content), 15 cc of wine (12% alcohol content), 4.5 cc of distilled spirit or liquor (40% alcohol content)];
  • Difficulty in communicating with the study staff due to speech, language, or (non-corrected) hearing and vision problems;
  • Severe arthritis (E.g., awaiting joint replacement) that would interfere with the ability to fully participate in the study;
  • Lung disease requiring regular use of supplemental oxygen;
  • Severe cardiovascular disease (including [NYHA] class III or IV, congestive heart failure and valvular disease, history of cardiac arrest, presence of an implantable defibrillator or pacemaker, uncontrolled angina);
  • Upper and/or lower extremity amputation;
  • Peripheral arterial disease Lériche-Fontaine 3 or 4;
  • Renal disease requiring dialysis;
  • Current enrolment in another study involving lifestyle, nutrition, or pharmaceutical interventions;
  • Further medical, psychiatric, or behavioural factors that in the judgment of the principal investigator may interfere with the study participation;
  • Further possible illnesses affecting the and reducing it to less than 24 months, corresponding to the study's length;
  • Clinical judgment concerning safety or non-compliance, as well as the conditions for which the use of the Sleep Profiler is not recommended (sensitivity of skin or scalp and/or open wounds on the forehead or scalp, allergic reactions to extended exposure to synthetic fabrics (e.g., polyester, rayon), upper respiratory infection or congestion, head circumference less than 21 or greater than 25 inches, forehead vertical measurement (from top of eyebrows to hairline) less than or equal to 2 inches or horizontal measurement (from hairline to hairline) less than or equal to 6 inches).
  • SPPB score \<3 at baseline.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Groups and cohorts

  • Physically frail sarcopenic older subjects
  • Healthy active older subjects
06

What researchers measure

Primary outcomes

  1. Incidence of physical and functional worsening

    Time frame: 12 months

Secondary outcomes

  1. Prevalence and incidence of sarcopenia

    Time frame: 24 months

  2. Prevalence of mild cognitive impairment (MCI) and cognitive frailty

    Time frame: 24 months

  3. Incidence of mild cognitive impairment (MCI) and cognitive frailty

    Time frame: 24 months

  4. Incidence of dementia in cognitive frail older individuals

    Time frame: 24 months

  5. Prevalence and incidence of recognised pre-frailty conditions

    Time frame: 24 months

  6. Prevalence and incidence of malnutrition, polypharmacy and multimorbidity

    Time frame: 24 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2025; primary completion for Nov 2027, 30 months later.

Of 71 non-industry observational studies under Sleep Wake Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 30 months is close to that.

Counting every sponsor, half of 82 studies reached it within 25 months; a quarter within 12 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2025
First posted
Apr 25, 2025
StartEst.
May 2025
Primary completionEst.
Nov 2027
CompletionEst.
Nov 2027
Last update
Apr 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06944600
Lead sponsor
University of Parma
Responsible party
Marcello Giuseppe Maggio (MD, PhD, Full Professor in Internal and Geriatric Medicine, University of Parma) — Principal investigator
First posted
Apr 25, 2025
Start date
May 2025 (estimated)
Primary completion
Nov 2027 (estimated)
Completion
Nov 2027 (estimated)
Last update
Apr 25, 2025

Study contacts

Marcello G Maggio
Contact
marcellogiuseppe.maggio@unipr.it
+39 0521 703916

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion